Cargando…
AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption
BACKGROUND: Osteoporosis is a metabolic bone disease. Osteoclasts are significantly involved in the pathogenesis of osteoporosis. AS-605240 (AS) is a small molecule PI3K-γ inhibitor and is less toxic compared to pan-PI3K inhibitors. AS also exerts multiple biological effects including anti-inflammat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150757/ https://www.ncbi.nlm.nih.gov/pubmed/37138583 http://dx.doi.org/10.2147/DDDT.S403231 |
_version_ | 1785035415268360192 |
---|---|
author | Sun, Jiacheng Cai, Guoping Shen, Jinlong Cheng, Pu Zhang, Jiapeng Jiang, Dengteng Xu, Xianquan Lu, Fangying Chen, Lihua Chen, Haixiao |
author_facet | Sun, Jiacheng Cai, Guoping Shen, Jinlong Cheng, Pu Zhang, Jiapeng Jiang, Dengteng Xu, Xianquan Lu, Fangying Chen, Lihua Chen, Haixiao |
author_sort | Sun, Jiacheng |
collection | PubMed |
description | BACKGROUND: Osteoporosis is a metabolic bone disease. Osteoclasts are significantly involved in the pathogenesis of osteoporosis. AS-605240 (AS) is a small molecule PI3K-γ inhibitor and is less toxic compared to pan-PI3K inhibitors. AS also exerts multiple biological effects including anti-inflammatory, anti-tumor, and myocardial remodeling promotion. However, the involvement of AS in the differentiation and functions of osteoclasts and the effect of AS in treating patients with osteoporosis is still unclear. PURPOSE: This study aimed to investigate if AS inhibits the differentiation of osteoclasts and resorption of the bones induced by M-CSF and RANKL. Next, we evaluated the therapeutic effects of AS on bone loss in ovariectomy (OVX)-induced osteoporosis mice models. METHODS: We stimulated bone marrow-derived macrophages with an osteoclast differentiation medium containing different AS concentrations for 6 days or 5μM AS at different times. Next, we performed tartrate-resistant acid phosphatase (TRAP) staining, bone resorption assay, F-actin ring fluorescence, real-time quantitative polymerase chain reaction (RT-qPCR), and Western blotting (WB). Next, MC3T3-E1s (pre-osteoblast cells) were differentiated to osteoblast by stimulating the cells with varying AS concentrations. Next, we performed alkaline phosphatase (ALP) staining, RT-qPCR, and WB on these cells. We established an OVX-induced osteoporosis mice model and treated the mice with 20mg/kg of AS. Finally, we extracted the femurs and performed micro-CT scanning, H&E, and TRAP staining. RESULTS: AS inhibits the formation of osteoclasts and resorption of bone triggered by RANKL by inhibiting the PI3K/Akt signaling pathway. Furthermore, AS enhances the differentiation of osteoblasts and inhibits bone loss due to OVX in vivo. CONCLUSION: AS inhibits osteoclast production and enhances osteoblast differentiation in mice, thus providing a new therapeutic approach for treating patients with osteoporosis. |
format | Online Article Text |
id | pubmed-10150757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-101507572023-05-02 AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption Sun, Jiacheng Cai, Guoping Shen, Jinlong Cheng, Pu Zhang, Jiapeng Jiang, Dengteng Xu, Xianquan Lu, Fangying Chen, Lihua Chen, Haixiao Drug Des Devel Ther Original Research BACKGROUND: Osteoporosis is a metabolic bone disease. Osteoclasts are significantly involved in the pathogenesis of osteoporosis. AS-605240 (AS) is a small molecule PI3K-γ inhibitor and is less toxic compared to pan-PI3K inhibitors. AS also exerts multiple biological effects including anti-inflammatory, anti-tumor, and myocardial remodeling promotion. However, the involvement of AS in the differentiation and functions of osteoclasts and the effect of AS in treating patients with osteoporosis is still unclear. PURPOSE: This study aimed to investigate if AS inhibits the differentiation of osteoclasts and resorption of the bones induced by M-CSF and RANKL. Next, we evaluated the therapeutic effects of AS on bone loss in ovariectomy (OVX)-induced osteoporosis mice models. METHODS: We stimulated bone marrow-derived macrophages with an osteoclast differentiation medium containing different AS concentrations for 6 days or 5μM AS at different times. Next, we performed tartrate-resistant acid phosphatase (TRAP) staining, bone resorption assay, F-actin ring fluorescence, real-time quantitative polymerase chain reaction (RT-qPCR), and Western blotting (WB). Next, MC3T3-E1s (pre-osteoblast cells) were differentiated to osteoblast by stimulating the cells with varying AS concentrations. Next, we performed alkaline phosphatase (ALP) staining, RT-qPCR, and WB on these cells. We established an OVX-induced osteoporosis mice model and treated the mice with 20mg/kg of AS. Finally, we extracted the femurs and performed micro-CT scanning, H&E, and TRAP staining. RESULTS: AS inhibits the formation of osteoclasts and resorption of bone triggered by RANKL by inhibiting the PI3K/Akt signaling pathway. Furthermore, AS enhances the differentiation of osteoblasts and inhibits bone loss due to OVX in vivo. CONCLUSION: AS inhibits osteoclast production and enhances osteoblast differentiation in mice, thus providing a new therapeutic approach for treating patients with osteoporosis. Dove 2023-04-27 /pmc/articles/PMC10150757/ /pubmed/37138583 http://dx.doi.org/10.2147/DDDT.S403231 Text en © 2023 Sun et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Sun, Jiacheng Cai, Guoping Shen, Jinlong Cheng, Pu Zhang, Jiapeng Jiang, Dengteng Xu, Xianquan Lu, Fangying Chen, Lihua Chen, Haixiao AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption |
title | AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption |
title_full | AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption |
title_fullStr | AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption |
title_full_unstemmed | AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption |
title_short | AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption |
title_sort | as-605240 blunts osteoporosis by inhibition of bone resorption |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150757/ https://www.ncbi.nlm.nih.gov/pubmed/37138583 http://dx.doi.org/10.2147/DDDT.S403231 |
work_keys_str_mv | AT sunjiacheng as605240bluntsosteoporosisbyinhibitionofboneresorption AT caiguoping as605240bluntsosteoporosisbyinhibitionofboneresorption AT shenjinlong as605240bluntsosteoporosisbyinhibitionofboneresorption AT chengpu as605240bluntsosteoporosisbyinhibitionofboneresorption AT zhangjiapeng as605240bluntsosteoporosisbyinhibitionofboneresorption AT jiangdengteng as605240bluntsosteoporosisbyinhibitionofboneresorption AT xuxianquan as605240bluntsosteoporosisbyinhibitionofboneresorption AT lufangying as605240bluntsosteoporosisbyinhibitionofboneresorption AT chenlihua as605240bluntsosteoporosisbyinhibitionofboneresorption AT chenhaixiao as605240bluntsosteoporosisbyinhibitionofboneresorption |